Bayer AG is expanding its recently established Precision Health unit beyond the US and Europe, starting with the launch of its Aspirin Heart Risk Assessment tool in Saudi Arabia.
Bayer Takes Its Aspirin-Branded Digital CVD Screening Tool To Saudi Arabia
Bayer Consumer Health's recently established Precision Health unit launches its Aspirin Heart Risk Assessment tool in Saudi Arabia. Developed in partnership with British medtech firm Huma Therapeutics, Bayer is planning to roll out the digital tool to other countries in the Middle East and also Latin America.
More from Digital Technologies
• By
Bayer Consumer Health hopes its new InflammAge saliva-based biomarker can help “revolutionize self-care and how people can manage their aging journey.”
• By
AI prowess “will not be a competitive advantage long-term. It's going to be table stakes. But there are people who are going to get there sooner and they will have an advantage for a while,” says C&D CEO Matthew Farrell. P&G’s investment in AI, meanwhile, produced its “Great Idea Generator proprietary platform.”
• By
Electronic product information should be “fully operational” within four years after the entry into force of the revised EU pharma legislation and should precede the phasing out of paper leaflets, proposes the Inter-Association Taskforce (IATF) on ePI. Once the new system is up and running, ePI should be implemented across the EU in a harmonized way, with all EU member states adopting the same standard, it says.
• By
Developed using Datair's Ambee climate data technology, Opella’s Pollen Passport presents users with an easy to use and interactive online visualization of air quality at holiday destinations across the world.
More from HBW Insight
• By
FDA says “extension affords covered entities the additional time necessary to ensure complete coordination across the supply chain in order to fully implement the final rule’s requirements—ultimately providing FDA and consumers with greater transparency and food safety.”
• By
BBB National Programs’ NAD and CARU divisions jointly reviewed the social media posts of New York firm Bubble Beauty, finding the company could support claims of safety, but not efficacy, of its skin care products for children under 13.
• By
Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.